Malik Fady Ibraham, the Executive Vice President of Research & Development at Cytokinetics, Inc., has recently made notable stock transactions that may influence perceptions of executive management within the company.
According to a filing submitted on October 20, 2026, Ibraham acquired 3,500 shares of Cytokinetics common stock at a price of $7.80 each. In a parallel transaction on the same day, he sold 3,500 shares at a significantly higher price of $64.01 each. Following these transactions, Ibraham holds a total of 153,902 shares of Cytokinetics.
Background
Cytokinetics, Inc., identified by the Central Index Key (CIK) number 0001061983, operates in the pharmaceutical preparations sector. The company is headquartered at 350 Oyster Point Boulevard, South San Francisco, CA. It focuses on developing treatments for diseases related to muscle function and has a fiscal year ending on December 31.
What the Filing Says
The SEC filing indicates that Ibraham's stock transactions were executed on October 20, 2026. The filing states, "I acquired 3,500 shares at $7.80 and sold 3,500 shares at $64.01." This reflects a strategic approach to managing his equity in the company.
Impact
This activity may be of interest to shareholders and potential investors as it reflects Ibraham's confidence in the company's future performance. The transactions could also influence how other executives and employees view their own stock holdings, potentially impacting morale and investment decisions within the company.
What's Next
The filing does not say what happens next.